Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 313 participants.

Also called NCT02104583

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 313 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02104583
  • EudraCT 2013-004430-15
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Denmark, Germany, Hungary, Israel, Netherlands, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02104583. Randomized; double masking; primary purpose treatment. Start 2014-09 (actual); primary completion 2016-09 (actual). Results posted on 2019-04-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator
Acronym
TEMPO
Condition
Ventricular Arrhythmia
Intervention (Drug)
Eleclazine
Intervention (Drug)
Placebo to match eleclazine
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct02104583
Content hash
b0c8665d81d49b006e48963cbae28f7a1cb7dd406396f6b86ca1f13cde27bb17